153 related articles for article (PubMed ID: 38915767)
1. New clinical insight in amyotrophic lateral sclerosis and innovative clinical development from the non-profit repurposing trial of the old drug guanabenz.
Ambrosini A; Dalla Bella E; Ravasi M; Melazzini M; Lauria G
Front Med (Lausanne); 2024; 11():1407912. PubMed ID: 38915767
[TBL] [Abstract][Full Text] [Related]
2. Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Bella ED; Tramacere I; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Filosto M; Giannini F; Granieri E; Bella V; Lunetta C; Mandrioli J; Mazzini L; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Volanti P; Lauria G
BMJ Open; 2017 Aug; 7(8):e015434. PubMed ID: 28801400
[TBL] [Abstract][Full Text] [Related]
3. The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.
Dalla Bella E; Bersano E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Filosto M; Giannini F; Spataro R; Lunetta C; Mandrioli J; Messina S; Monsurrò MR; Mora G; Riva N; Rizzi R; Siciliano G; Silani V; Simone I; Sorarù G; Tugnoli V; Verriello L; Volanti P; Furlan R; Nolan JM; Abgueguen E; Tramacere I; Lauria G
Brain; 2021 Oct; 144(9):2635-2647. PubMed ID: 33905493
[TBL] [Abstract][Full Text] [Related]
4. Guidelines, editors, pharma and the biological paradigm shift.
Singh AR; Singh SA
Mens Sana Monogr; 2007 Jan; 5(1):27-30. PubMed ID: 22058616
[TBL] [Abstract][Full Text] [Related]
5. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
6. Drug Repurposing: A Network-based Approach to Amyotrophic Lateral Sclerosis.
Fiscon G; Conte F; Amadio S; Volonté C; Paci P
Neurotherapeutics; 2021 Jul; 18(3):1678-1691. PubMed ID: 33987813
[TBL] [Abstract][Full Text] [Related]
7. Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis.
Wang L; Popko B; Tixier E; Roos RP
Neurobiol Dis; 2014 Nov; 71():317-24. PubMed ID: 25134731
[TBL] [Abstract][Full Text] [Related]
8. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Jiang HQ; Ren M; Jiang HZ; Wang J; Zhang J; Yin X; Wang SY; Qi Y; Wang XD; Feng HL
Neuroscience; 2014 Sep; 277():132-8. PubMed ID: 24699224
[TBL] [Abstract][Full Text] [Related]
9. TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro.
Duan QQ; Wang H; Su WM; Gu XJ; Shen XF; Jiang Z; Ren YL; Cao B; Li GB; Wang Y; Chen YP
BMC Med; 2024 Mar; 22(1):96. PubMed ID: 38443977
[TBL] [Abstract][Full Text] [Related]
10. Induced pluripotent stem cells-based disease modeling, drug screening, clinical trials, and reverse translational research for amyotrophic lateral sclerosis.
Okano H; Morimoto S; Kato C; Nakahara J; Takahashi S
J Neurochem; 2023 Dec; 167(5):603-614. PubMed ID: 37952981
[TBL] [Abstract][Full Text] [Related]
11. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
12. Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design.
Fournier CN
Neurotherapeutics; 2022 Jul; 19(4):1180-1192. PubMed ID: 35819713
[TBL] [Abstract][Full Text] [Related]
13. Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.
Sattler R; Traynor BJ; Robertson J; Van Den Bosch L; Barmada SJ; Svendsen CN; Disney MD; Gendron TF; Wong PC; Turner MR; Boxer A; Babu S; Benatar M; Kurnellas M; Rohrer JD; Donnelly CJ; Bustos LM; Van Keuren-Jensen K; Dacks PA; Sabbagh MN;
Neurol Ther; 2023 Dec; 12(6):1821-1843. PubMed ID: 37847372
[TBL] [Abstract][Full Text] [Related]
14. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
15. Can Some Anticancer Drugs Be Repurposed to Treat Amyotrophic Lateral Sclerosis? A Brief Narrative Review.
Potenza RL; Armida M; Popoli P
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339026
[TBL] [Abstract][Full Text] [Related]
16. Signature-Based Computational Drug Repurposing for Amyotrophic Lateral Sclerosis.
Papikinos T; Krokidis MG; Vrahatis A; Vlamos P; Exarchos TP
Adv Exp Med Biol; 2023; 1424():201-211. PubMed ID: 37486495
[TBL] [Abstract][Full Text] [Related]
17. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches.
Kukharsky MS; Skvortsova VI; Bachurin SO; Buchman VL
Med Res Rev; 2021 Sep; 41(5):2804-2822. PubMed ID: 32815157
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
19. Randomized double-blind personalized N-of-1 clinical trial to test the safety and potential efficacy of TJ-68 for treating muscle cramps in amyotrophic lateral sclerosis (ALS): study protocol for a TJ-68 trial.
Mitsumoto H; Cheung K; Oskarsson B; Andrews HF; Jang GE; Andrews JA; Shah JS; Fernandes JA; McElhiney M; Santella RM
Trials; 2023 Jul; 24(1):449. PubMed ID: 37430314
[TBL] [Abstract][Full Text] [Related]
20. Drug repurposing: a systematic review on root causes, barriers and facilitators.
Krishnamurthy N; Grimshaw AA; Axson SA; Choe SH; Miller JE
BMC Health Serv Res; 2022 Jul; 22(1):970. PubMed ID: 35906687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
